Transparency Disclosures

A photograph of a healthcare worker and patient reviewing information together at a computer in a clinic
style
background-none
additionalPadding
none
user icon

Our experience has taught us that transparency in
our operations can help to build trust with
stakeholders.

Transparency can also guard against corruption and unethical business practices. By listening
and responding openly to our stakeholders’ concerns, we can improve our transparency and the
way we do business.
style
background-primary-red
additionalPadding
narrow
Scientist working in lab

We became the first pharmaceutical company to voluntarily launch an online clinical trial registry.

Since 2002, Lilly has registered all Lilly-sponsored Phase II, Phase III and Phase IV clinical studies, conducted anywhere in the world that were initiated on or after October 15, 2002, on www.clinicaltrials.gov. Additionally, Lilly began registering all Phase I clinical studies commencing on or after October 1, 2010.
style
background-none
additionalPadding
narrow
style
background-none
additionalPadding
narrow

We believe that transparency of business practices that involve
financial payments, or other forms of value, to physicians is
essential for building trust.

As a result, we have taken a number of steps to provide information on important aspects of how we interact with key
partners in the pursuit of advancements in medicine.

Since 1 October 2015, all member companies of Medicines Australia were required to report information relating to any
healthcare professional who receives payment for consulting or speaker services and any support to attend educational
events. As a member company of Medicines Australia, Lilly also provides to Medicines Australia for publication on its
website:

  • A report listing health consumer organisations to which it provides financial support and/
    or significant direct/indirect non-financial support.
  • A report listing third party meetings and symposia to which it provides financial support to, as well as grants and donations made to third party organisations.
style
background-none
additionalPadding
narrow
style
background-none
additionalPadding
narrow

Transparency disclosures

style
background-none, two-col-75-25
extra-styles
offset
currency circle dollar
Payments and transfers of
value to healthcare professionals
tile, title-fs-32px, ctaselection-link, ctatarget-newtab, ctaexitinterstitial-general-third-parties
View reports
graduation
Third party meeting sponsorships, grants and donations
tile, title-fs-32px, ctaselection-link, ctatarget-newtab, ctaexitinterstitial-general-third-parties
View reports
user icon
Health consumer organisation support
tile, title-fs-32px, ctaselection-link, ctatarget-newtab, ctaexitinterstitial-general-third-parties
View reports
style
background-none
additionalPadding
narrow

Man in manufacturing

Ethics & Compliance

Learn more
CMAT-25521 | May 2026
style
background-none
additionalPadding
narrow